Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F23%3AN0000163" target="_blank" >RIV/00027162:_____/23:N0000163 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60077344:_____/23:00579681 RIV/00216224:14310/23:00132670 RIV/62157124:16170/23:43881032

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0264410X23010897?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0264410X23010897?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.vaccine.2023.09.019" target="_blank" >10.1016/j.vaccine.2023.09.019</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs

Popis výsledku v původním jazyce

Tick-borne encephalitis (TBE) is a severe neuroinfection of humans that occurs in Europe and Asia. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV) in TBE-endemic areas. These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this unmet need, we have developed a TBEV vaccine candidate for dogs based on inactivated whole virus antigen. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both animal species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.

Název v anglickém jazyce

Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs

Popis výsledku anglicky

Tick-borne encephalitis (TBE) is a severe neuroinfection of humans that occurs in Europe and Asia. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV) in TBE-endemic areas. These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this unmet need, we have developed a TBEV vaccine candidate for dogs based on inactivated whole virus antigen. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both animal species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10607 - Virology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Vaccine

ISSN

0264-410X

e-ISSN

1873-2518

Svazek periodika

41

Číslo periodika v rámci svazku

42

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

6150-6155

Kód UT WoS článku

001089063300001

EID výsledku v databázi Scopus

2-s2.0-85171657807